Since the 1990s, the prostate specific antigen (PSA) test has been used routinely to screen men for prostate cancer. However, last May the US Preventive Services Task Force (USPSTF) published a recommendation that “there is moderate certainty that the benefits of PSA-based screening do not outweigh the harms.” The USPSTF opinion sparked heated debate among the medical community. For example, the American Urological Association (AUA) promptly refuted the decision and asserted the benefits far outweighed the risks.
On January 27, The U.S. Food and Drug Administration (FDA) announced that it had approved Inlyta (axitinib), manufactured by Pfizer, Inc., for the treatment of patients with advanced renal cell carcinoma (kidney cancer) who have not responded to other medical treatments. Inlyta works by blocking certain proteins, known as kinases, which play a role in tumor growth and cancer progression. Inlyta is an oral medication that is taken twice daily.